---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-22-000067"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:38:51.489534+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q1 net loss $12.2M; revenue $38k; PreTRM orders rise

## Summary
- Revenue of $38k in Q1 2022 vs $13k in Q1 2021; still minimal.
- Net loss widened to $12.2M from $6.4M; operating expenses $12.3M vs $6.0M.
- Cash and securities total $129.9M as of March 31, 2022.
- Simplified PreTRM ordering process; order trends improving into Q2.
- Preeclampsia biomarker validation expected mid-2022; PRIME study on track for 2023 interim readout.

## SEC filing metadata
- accession: 0001534969-22-000067
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000067/0001534969-22-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000067/sera-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-22-000067
- JSON: https://secwatch.observer/filing/0001534969-22-000067.json
- Plain text: https://secwatch.observer/filing/0001534969-22-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.